The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|May 2, 2020
- Pharmaceutical Technology-05-02-2020
- Volume 44
- Issue 5
Pre-Packed Columns
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
Tosoh Bioscience introduced the SkillPak 1 mL and 5 mL pre-packed columns for fast method development and resin screening of monoclonal antibodies, antibody constructs, oligonucleotides, proteins, and viruses.
The columns come pre-packed with Toyopearl, TSKgel, or Ca++Pure-HA process chromatography media and are ready for use immediately. Additionally, the high performance, scalable columns are available with short delivery times in affinity, anion and cation exchange, hydrophobic interaction, and size exclusion chromatographic modes. Peak performance is guaranteed, according to the company, and the columns can be operated directly with low- or medium-pressure liquid chromatography systems.
Articles in this issue
over 6 years ago
Modern Drug Manufacturing Key to COVID-19 Responseover 6 years ago
How Fast Is Too Fast?over 6 years ago
Starting a Career in the Bio/Pharmaceutical Industryover 6 years ago
Can We Teach an Old Drug New Tricks?over 6 years ago
Good Manufacturing Practices: Aseptic and Sterile Processingover 6 years ago
Small-Volume Conversion Kit for Bathless Dissolution Testersover 6 years ago
Inline High Shear Mixersover 6 years ago
Laser-Marked Smart ContainersRelated to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.